SynAct Pharma AB (publ) (”SynAct”) (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, today announced that it will host a Capital Markets Day on March 11, 15:00-17:00 CET in Stockholm.
“With key clinical data expected from the ADVANCE study and ongoing studies in respiratory viral infections and dengue virus, we are looking at a particularly busy and transformative year for SynAct,” said Jeppe Øvlesen, Chief Executive Officer, SynAct Pharma
The capital markets day will provide investors, analysts, and the media with an update on SynAct’s clinical development programs and priorities focused on resomelagon applications in rheumatoid arthritis and respiratory viral infections.
When: March 11, 2026, from 15:00-17:00 CET
Location: Investor Studios, Hötorgsskrapan 3
Address: Sveavägen 9 or Mäster Samuelsgatan 42 or Sergelgatan 8 – 10, Floor 7
Further details regarding the agenda, speakers, livestream link, and registration will be communicated closer to the event.